Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) muestra la lectura de resultados positivos del ensayo RELIEF Phase 3 de TNX-102 SL para controlar la fibromialgia en la conferencia anual de ACSP
biopharmajournal.com
Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) Shows Readout Of Positive Results From RELIEF Phase 3 Trial Of TNX-102 SL To Manage Fibromyalgia At The Annual Conference Of ACSP
Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) presented a readout of the positive results from the Phase 3 Clinical trial, RELIEF study, of TNX-102 SL to manage fibromyalgia effectively. The 2021 ACSP annual conference presentation is under the title – safety and efficacy of the Sublingual...
biopharmajournal.com